The FA-BRCA Pathway and Response to Platinum and PARP Inhibitors in Ovarian, Tubal and Peritoneal Carcinomas

Project: Research project

Project Details


Ovarian carcinoma is the most deadly gynecologic cancer, causing almost 15,000 deaths annually in the U.S. Most women with ovarian cancer are treated with a combination of surgery and platinum chemotherapy. Even though the majority of women respond well to this treatment initially, eventually their cancers recur and develop resistance to platinum and other types of chemotherapy. Accordingly, new treatment modalities are urgently needed for both primary and recurrent disease.
Effective start/end date1/1/1312/31/15


  • Ovarian Cancer Research Alliance: $300,000.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.